In: Crohn's disease22 Aug 2012
Ehrenpreis et al also published an open-label trial on refractory Crohn’s disease and during the trial the results were considered to be excellent. These were both open-label trials, and I have no knowledge of a double-blind placebo controlled trial with this drug as yet.
Since these reports, numerous other case reports and reviews on thalidomide have been the subject of numerous articles in the literature. Bousvarous and Mueller reviewed the use of thalidomide in gastrointestinal disorders. Odeka and Miller published a discussion of the use of thalidomide in oral Crohn’s disease that was refractory to conventional medical treatment. All of these authors state that thalidomide in doses of 50 mg/day to 300 mg/day may decrease the severity of mucosal disease and prompt closure of fistulae. All authors state that patients who are placed on thalidomide therapy must practise either abstinence or strict birth control.
Women also must undergo regular pregnancy testing and use at least two forms of contraception. Bariol et al reported on the early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. They felt that their data suggested that thalidomide was an effective short term treatment for refractory inflammatory bowel disease. I could find no reports that men should not have sexual relations when taking thalidomide and none of the reports I reviewed made mention of it. Get most advantageous deals ever – purchase Tavist waiting for you round the clock.
Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.